» Articles » PMID: 38835501

Invasive Group A Streptococcal Disease Surveillance in Canada, 2021-2022

Abstract

Background: Invasive group A streptococcal (iGAS, ) disease has been a nationally notifiable disease in Canada since 2000. This report summarizes the demographics, types, and antimicrobial resistance of iGAS isolates collected in Canada in 2021 and 2022.

Methods: The Public Health Agency of Canada's National Microbiology Laboratory collaborates with provincial and territorial public health laboratories to conduct national surveillance of invasive . typing was performed using the Centers for Disease Control and Prevention sequencing protocol or extracted from whole-genome sequencing data. Antimicrobial susceptibilities were determined using Kirby-Bauer disk diffusion according to Clinical and Laboratory Standards Institute guidelines or predicted from whole-genome sequencing data based on the presence of resistance determinants.

Results: Overall, the incidence of iGAS disease in Canada was 5.56 cases per 100,000 population in 2021, decreasing from the peak of 8.6 cases per 100,000 population in 2018. A total of 2,630 iGAS isolates were collected during 2022, representing an increase from 2021 (n=2,179). In particular, there was a large increase in isolates collected from October to December 2022. The most predominant type overall in 2021 and 2022 was 49, at 21.5% (n=468) and 16.9% (n=444), respectively, representing a significant increase in prevalence since 2018 (<0.0001). The former most prevalent type, 1, increased from 0.5% (n=10) in 2021 to 4.8% (n=125) in 2022; similarly, 12 increased from 1.0% (n=22) in 2021 to 5.8% (n=151) in 2022. These two types together accounted for almost 25% of isolates collected in late 2022 (October to December). Antimicrobial resistance rates in 2021 and 2022 included: 14.9%/14.1% erythromycin resistance, 4.8%/3.0% clindamycin resistance, and <1% chloramphenicol resistance.

Conclusion: The increase of iGAS isolates collected in Canada is an important public health concern. Continued surveillance of iGAS is critical to monitor expanding types and antimicrobial resistance patterns.

Citing Articles

Molecular and Clinical Characterization of Invasive Isolates: Insights from Two Northern-Italy Centers.

Bonomo C, Mannino E, Bongiorno D, Vocale C, Amicucci A, Bivona D Pathogens. 2025; 14(2).

PMID: 40005528 PMC: 11857904. DOI: 10.3390/pathogens14020152.


Group A streptococcal infections in Alberta, Canada 2018-2023.

Tyrrell G, Croxen M, McCullough E, Li V, Golden A, Martin I Epidemiol Infect. 2024; 153:e35.

PMID: 39711024 PMC: 11869071. DOI: 10.1017/S0950268824001857.


Group A Streptococcus Infections in Children: Epidemiological Insights Before and After the COVID-19 Pandemic.

Karapati E, Tsantes A, Iliodromiti Z, Boutsikou T, Paliatsiou S, Domouchtsidou A Pathogens. 2024; 13(11).

PMID: 39599560 PMC: 11597688. DOI: 10.3390/pathogens13111007.


Invasive Group A Streptococcus Hypervirulent M1 Clone, Canada, 2018-2023.

Golden A, Griffith A, Tyrrell G, Kus J, McGeer A, Domingo M Emerg Infect Dis. 2024; 30(11):2409-2413.

PMID: 39428565 PMC: 11521172. DOI: 10.3201/eid3011.241068.

References
1.
Amarsy R, Fournier S, Trystram D, Monteil C, Raynaud X, Jarlier V . Decrease of hospital- and community-acquired bloodstream infections due to Streptococcus pneumoniae and Streptococcus pyogenes during the first year of the COVID-19 pandemic: A time-series analysis in Paris region. Am J Infect Control. 2022; 51(4):475-477. PMC: 9474397. DOI: 10.1016/j.ajic.2022.09.002. View

2.
Li Y, Rivers J, Mathis S, Li Z, McGee L, Chochua S . Continued Increase of Erythromycin Nonsusceptibility and Clindamycin Nonsusceptibility Among Invasive Group A Streptococci Driven by Genomic Clusters, United States, 2018-2019. Clin Infect Dis. 2022; 76(3):e1266-e1269. PMC: 11120049. DOI: 10.1093/cid/ciac468. View

3.
Jacob J, Bocking N, Hummelen R, Poirier J, Kelly L, Madden S . The development of a community-based public health response to an outbreak of post-streptococcal glomerulonephritis in a First Nations community. Can Commun Dis Rep. 2021; 47(7-8):339-346. PMC: 8340670. DOI: 10.14745/ccdr.v47i78a07. View

4.
Golden A, Griffith A, Demczuk W, Tyrrell G, Kus J, McGeer A . Invasive group A streptococcal disease surveillance in Canada, 2020. Can Commun Dis Rep. 2023; 48(9):407-414. PMC: 10723789. View

5.
Demczuk W, Martin I, Domingo F, Macdonald D, Mulvey M . Identification of Streptococcus pyogenes M1 clone in Canada. Lancet Infect Dis. 2019; 19(12):1284-1285. DOI: 10.1016/S1473-3099(19)30622-X. View